Calibration material delivery devices and methods

Information

  • Patent Grant
  • 8919605
  • Patent Number
    8,919,605
  • Date Filed
    Tuesday, November 30, 2010
    14 years ago
  • Date Issued
    Tuesday, December 30, 2014
    9 years ago
Abstract
These are devices and methods of delivering calibration or control information to a device, such as an analyte monitor. The devices may include a first portion configured to be grasped by the hand of the user, and a second portion including a reservoir and a flexible neck. The reservoir may contain a control material that contains a target analyte in a known or predetermined concentration.
Description
FIELD

The inventions described herein relates to devices and methods of delivering calibration or control information to a device, such as an analyte monitor.


BACKGROUND

In this specification where a document, act or item of knowledge is referred to or discussed, this reference or discussion is not an admission that the document, act or item of knowledge or any combination thereof was at the priority date, publicly available, known to the public, part of common general knowledge, or otherwise constitutes prior art under the applicable statutory provisions; or is known to be relevant to an attempt to solve any problem with which this specification is concerned.


Currently, analyte monitoring devices, such as blood glucose monitors, include a method of executing a “control fluid” test to determine if the device is functioning according to the manufacturer's expectations. Typically, users complete a “control” test by dispensing a variable amount of fluid onto a test strip from a vial packaged with the test kit. This vial contains a fluid within a known analyte concentration. After the users dispense the fluid onto the test strip the analyte monitor assumes the fluid is a body fluid and provides a result as usual. The device and/or the user can compare the concentration of target analyte measured by the device with the known concentration contained in the control solution as a measure of the accuracy of the monitoring device.


Current systems require the user to dispense the calibration fluid from a vial containing several doses of calibration fluid. When dispensing the fluid the user must take care not to spill the fluid on the device, or on the testing surface. Completing a control test also requires that users have the dexterity to deliver a small droplet of control solution from a vial onto the test strip; this is especially difficult when diseases such as diabetes affect the patient's vision and tactile sensation.


A typical calibration or control test requires the following steps:

    • 1. users find their control vial
    • 2. ensure that the control solution is still within its expiration limits
    • 3. find a test strip
    • 4. insert the test strip into the device or meter
    • 5. place the device into “control test mode” (if applicable)
    • 6. shake the bottle of solution
    • 7. open the control vial (using two-hands)
    • 8. carefully squeeze out enough control solution onto the test strip or the finger, taking care not to damage the analyte monitor by dispensing too much fluid
    • 9. accurately deliver the control solution to the analyte monitor
    • 10. compare the result of the control test versus the stated control range which may or may not be listed on the control vial
    • 11. mark the control test in their logbook so that health care professionals can remove this test from the users monthly averages if so desired.


Currently many users of analyte monitors find executing a control test to be a burdensome experience that they often ignore. By ignoring the control test users often will acquire erroneous information from their monitors, and this information may then be used to adjust drug treatments. The use of inaccurate information can lead to serious consequesnces, such as hypoglycemia in diabetes patients from a dosage of insulin that is too high.


While certain aspects of conventional technologies have been discussed to facilitate disclosure of the invention, Applicants in no way disclaim these technical aspects, and it is contemplated that the claimed invention may encompass or include one or more of the conventional technical aspects discussed herein.


SUMMARY

As used herein, “body fluid” encompasses whole blood, interstitial fluid, and mixtures thereof.


As used herein “integrated device” or “integrated meter” means a device or meter that includes all components necessary to perform sampling of body fluid, transport of body fluid, quantification of an analyte, and display of the amount of analyte contained in the sample of body fluid. Exemplary integrated meters are described in: U.S. Pat. Nos. 6,540,675 and 7,004,928; U.S. Patent Application Publication Nos. US 2008/0077048, US 2007/0179404, US 2007/0083131, US 2007/0179405, US 2007/0078358, and US 2007/0078313. The entire contents of each of the above-listed documents are incorporated herein by reference.


As used herein, “control material” means a material having a known and/or predetermined quantity or concentration of at least one, and possibly a plurality of, analyte(s) contained therein. The material can possess any suitable form. For example, the control material can be in the form of a liquid, a solid, a granular solid, a gas, a gel, a solution, a suspension, or any combination thereof. The analyte can comprise any suitable analyte. For example, the analyte can comprise one or more of: glucose, bilirubin, alcohol, controlled substances, toxins, hormones, and/or proteins.


It is to be understood that reference herein to first, second, third and fourth components (etc.) does not limit the present invention to embodiments where each of these components is physically separable from one another. For example, a single physical element of the invention may perform the functions of more than one of the claimed first, second, third or fourth components. Conversely, a plurality of separate physical elements working together may perform the functions of one of the claimed first, second, third or fourth components. Similarly, reference to first, second (etc.) method steps does not limit the invention to only separate steps. According to the invention, a single method step may satisfy multiple steps described herein. Conversely, a plurality of method steps could, in combination, constitute a single method step recited herein. In addition, the steps of the method are not necessarily limited to the order in which they are described or claimed herein.


It should also be understood that references herein to “the invention,” or similar language, is used to enhance readability and for convenience only, and should not be interpreted as a limitation on what is contemplated and comprehended by this disclosure and the appended claims. Instead “the invention” is intended to be interpreted as encompassing the full scope of what is claimed, regardless of the characterizations of the specific exemplary and non-limiting embodiments described in the specification.


The present invention may address one or more of the problems and deficiencies of the prior art discussed above. However, it is contemplated that the invention may prove useful in addressing other problems and deficiencies, or provides benefits and advantages, in a number of technical areas. Therefore the claimed invention should not necessarily be construed as being limited to addressing any of the particular problems or deficiencies discussed herein.


The invention can be useful with any device, but is particularly applicable to analyte monitors used in a home or clinical setting such as glucose monitors. The invention provides users of such monitors with a device that allows them to quickly and easily deliver one or more doses of calibration or control information to one or more devices, such as an analyte monitor. The invention also provides for mechanisms and methods that can automatically differentiate a calibration test from a typical test. This invention is aimed at devices requiring calibration or the ability to execute a control test. For example, in the case of analyte monitors where an analyte of a known concentration is delivered to the analyte monitor to ensure that it is functioning properly. According to the principles of the present invention, a typical user can easily and quickly execute a proper calibration test to ensure device functionality without assistance from a trained health care professional. Alternatively, the present invention can also be utilized by medical professionals in a clinical setting.


The invention can be used with an integrated device or integrated meter of the type defined above. However, the invention is not limited to use with fully integrated meters, and benefits can also be attained by use with conventional (non-integrated) meters and other diagnostic devices where collection of accurate data and analysis of data is important.


The invention can provide a device containing a single dosage, or multiple doses of control material in a convenient easy-to-use package. The control material can be contained within an applicator that is large enough for easy handling and sealed according to a number of alternative ways so that the risk of spillage or damage to the analyte monitor is greatly reduced.


This device simplifies a control test and encourages users to perform a control test more often so that any problems with their analyte monitors can be found more quickly.


The invention can provide for use of one or more dosage(s) of a predefined volume of control material, thereby ensuring more accurate data by allowing users to deliver the required amount of control solution, unlike previous methods in which it is quite possible that users could deliver too much or too little control solution. As previously mentioned, by sealing each dosage individually the viability of the control sample can be enhanced and users are less likely to use expired control material. The accuracy of the average data stored within the analyte monitor can also be increased by automatically marking or differentiating a control test from a normal or actual test so that the control test value can not impact the averages of normal analyte testing (weekly, monthly, etc) stored within the unit.


According to certain aspects, the invention provides mechanisms and methods that can determine automatically if the sampled material is body fluid or control material without the user's intervention. Also, the individual packaging of each control test ensures that each solution dosage will remain enclosed in a protective environment and allows for an extended expiration date.


According to a first aspect, the present invention provides a device comprising: a first portion configured to be grasped by the hand of the user; and a second portion defining a reservoir containing a first control material, wherein the control material comprises a target analyte of a known or predetermined concentration.


According to another aspect, the present invention provides in combination, an integrated meter comprising a housing with an opening formed therein, and the device as described above, the second portion comprising a body and a flange shaped and configured to be received by the integrated meter.


According to an additional aspect, the present invention provides a method of conveying a control material to an analyte monitor, the method comprising: (i) providing a dispenser comprising a first portion configured to be grasped by the hand of the user, and a second portion defining a reservoir having a frangible seal thereon, the reservoir containing a control material, wherein the control material contains a target analyte in a known and/or predetermined concentration; (ii) breaking the frangible seal; and (iii) conveying the control material to a location for analysis by the analyte monitor.


According to another aspect, the present invention provides a method of verifying the accuracy of the operation of an analyte monitoring device using a control material having a known and/or predetermined concentration of at least one analyte, the method comprising: providing a single or multi-test cartridge having information associated therewith defining an acceptable range of measured analyte concentration values for the control material; associating the single or multi-test cartridge with the device; reading the information off the single or multi-test cartridge; introducing a control material to the single or multi-test cartridge; the device automatically determining the presence of a control material; analyzing the control material to measure the concentration of analyte contained therein; and comparing the measured concentration with the control information to determine if the measured concentration corresponds to the acceptable range of concentration values obtained from the information.





BRIEF DESCRIPTION OF THE DRAWING FIGURES

The following description of exemplary embodiments can be read in connection with the accompanying drawings in which like numerals designate like elements and in which:



FIG. 1 is a side view of a device formed according to one embodiment of the present invention.



FIG. 2 is a sectional view taken at line A-A of FIG. 1.



FIG. 3 is a bottom view of the device of FIG. 1.



FIG. 4 is a schematic illustration of a device and a possible implementation, use or method involving the device, according to further alternative embodiments.



FIG. 5 is a side view of a device formed according to an additional alternative embodiment of the present invention.



FIG. 6 is a sectional view taken at line A-A of FIG. 5.



FIG. 7 is a perspective view of the device of FIG. 5.



FIG. 8 is an exploded perspective view of the device of FIG. 5.



FIG. 9 is a perspective view of a device formed according to another embodiment of the present invention.



FIG. 10 is a perspective view of one of the individual devices of FIG. 9.



FIG. 11 is a top view of one of the individual devices of FIG. 9.



FIG. 12 is a side view of one of the individual devices of FIG. 9.



FIG. 13 is a bottom view of one of the individual devices of FIG. 9.



FIG. 14 is a side view of a device formed according to a further embodiment of the invention.



FIG. 15 is an edge view of the device of FIG. 14.



FIG. 16 is a longitudinal sectional view of the device of FIG. 14.



FIG. 17 is an exploded view of the device of FIG. 14.



FIG. 18 is a longitudinal sectional view of an alternative embodiment of a device according to the present invention.



FIG. 19 is a side view of a further alternative embodiment of a device formed according to the present invention.



FIG. 20 is a longitudinal sectional view of the device of FIG. 19.



FIG. 21 is a longitudinal sectional view of an additional alternative embodiment of a device of the present invention in a first state.



FIG. 22 is a longitudinal sectional view of the device of FIG. 20, in a second state.



FIG. 23 is a side view of a yet another embodiment of a device formed according to the invention.



FIG. 24 is a longitudinal sectional view of the device of FIG. 23.



FIG. 25 is a sectional view of a further alternative embodiment of a device of the present invention.



FIG. 26 is an enlargement of the detail of area B in FIG. 25.



FIG. 27 is a schematic illustration of certain techniques and mechanisms for providing calibration information.



FIGS. 28A-28D illustrate a method and possible uses of a device according to further alternative embodiments of the present invention.



FIGS. 29A-29D illustrate an alternative method and possible uses of a device according to additional alternative embodiments of the present invention.



FIGS. 30A-30B illustrate an additional alternative method and possible uses of a device according to further alternative embodiments of the present invention.





DETAILED DESCRIPTION

In general terms this invention describes a device that allows a user to deliver a one or more doses of control material, such as a control fluid or control solution, to one or more devices such as a meter or monitor, for example, an integrated blood glucose monitor previously described herein. The method of and apparatus for delivery of the control solution can take many forms, such as a prepackaged “blister” of control solution or a “wand,” with a known predetermined volume of control solution available for delivery to the analyte monitor. Exemplary, non-limiting embodiments of the present invention are illustrated in Figures which follow.


As illustrated in FIGS. 1-4, a device 10 constructed according to a first illustrated embodiment comprises two portions; a first portion 12 and a second portion 14. The first portion 12 serves primarily as a handle for manipulation of the device 10 by a user. Thus, the first portion 12 can be provided with any suitable form which provides the desired functionality. Therefore, it should be evident that the form of the first portion 12 is not limited to the illustrated embodiment. According to the non-limiting illustrated embodiment, the first portion 12 is in the form of an elongated cylindrical body.


The second portion 14 provides a mechanism for carrying a control or calibration material, as well as optionally mating with a meter or monitor (see, e.g. FIG. 4). Thus, the second portion 14 can have any suitable form that provides this functionality. According to the nonlimiting illustrated embodiment, the second portion 14 defines a reservoir 16. The reservoir 16 can have any suitable form, and is not limited to the form shown in the illustrated embodiment. The reservoir contains a control material. Any suitable control material can be utilized. The control material comprises a target analyte, such as glucose, in a known and/or predetermined concentration. Optionally, the control material may contain a plurality of target analytes. According to one alternative embodiment, the control material is in the form of a control liquid or solution. According to a further alternative embodiment, the control material is in the form of a liquid or solution that is carried by an absorbent or porous material, such as a sponge-like material. Thus, according to the one optional embodiment, the control material 18 is in the form of an absorbent or porous material having a control liquid, suspension or solution absorbed therein.


The reservoir 16 containing the control material 18 can be provided with a closure or seal 20. The closure or seal 20 acts to contain the control material 18 within the reservoir 16, and to prevent contamination by shielding the control material 18 from the environment. The closure or seal 20 can be provided in any suitable form, and can be constructed of any suitable material. According to one non-limiting example, the closure or seal 20 can be in the form of a thin, frangible, closure, such as a metallic foil.


As noted above, according to one optional embodiment, the second portion 14 serves to mate with an analyte monitor such that the control material 18 can be dispensed. Thus, the second portion can be provided with a shape and size that renders it suitable for mating with a meter or monitor. It should be evident that the construction of the particular device with which the second portion 14 will mate can influence both the size and shape of the second portion 14. According to the nonlimiting illustrated example, the second portion 14 comprises a flanged 22 cylindrical body 24, as perhaps best seen in FIG. 3, which is dimensioned to mate with an opening formed in an analyte monitor, as best illustrated in FIG. 4. Thus, according to one possible implementation or embodiment of the present invention, an opening is formed in an analyte monitor by a flexible footprint or interface device 26 which is mounted to the housing 28 of the meter or monitor. The body 24 of the second portion 14 of the device 10 is inserted into the opening to a desired depth, which is controlled or defined by the location of the flange 22. According to one non-limiting example, the analyte monitor includes a piercing element, or hollow needle, 30 which can be actuated such that it breaks the seal 20 and comes into fluid communication with the control material 18. The hollow piercing element 30 then transports the control material 18 into the analyte monitor, as indicated by the arrow appearing in FIG. 4, wherein the monitor includes an appropriate mechanism for analyzing the control material to measure the concentration of the target analyte(s) contained therein. Such mechanisms may include electrochemical or colorimetric analysis, as described in connection with the description of the integrated meters previously referenced herein.


A device constructed according to further alternative embodiments of the present invention is depicted in FIGS. 5-8. The device has a construction and functionality which is similar to that of the previously described embodiments. Therefore, where a feature of the alternative embodiments finds a corresponding feature with the previously described embodiments, they have been given similar reference numeral (e.g., 12 and 112). Therefore, reference is made to the previously described embodiments for a full description of these corresponding features.


As illustrated in FIGS. 5-8, the first portion 112 of the device 100 is provided with a configuration which facilitates handling by a user. This is particularly important when the device 100 is intended for use with blood glucose monitors. This is because people with diabetes can lack tactile dexterity. Thus, the first portion 112 of the device 100 can be provided with any suitable form which facilitates grasp by a user.


According to the illustrated embodiment, the first portion 112 comprises a flattened relatively wide paddle-like shape. The paddle-like shape includes facing surfaces 113 which are contoured in an hourglass type manner such that the second portion 112 is provided with a cross-section that is relatively thin toward the middle, and wider towards its ends (FIG. 6). The second portion 112 may optionally be provided with a feature that reduces slippage. For example, according to the nonlimiting illustrated embodiment, the second portion 112 is provided with a series of raised projections or ribs 115. Alternative features, such as a high friction surface coating or material disposed on all or a portion of surfaces 113 and/or ribs 115 may also be provided.


The second portion 114 of the device 100 defines a reservoir 116, which houses a control material 118, which can take any suitable form, such as that described in connection with the previous embodiments. The reservoir 116 can be sealed by a corresponding closure or seal 120. The second portion 114 further comprises a flanged 122 body 124, configured in a manner similar to that of the previously described embodiment.


In the embodiments depicted in FIGS. 5-8, the first portion 112 in the second portion 114 are formed as separate components which are assembled together and secured in any suitable fashion, such as by adhesive or a fastener. However, it should be understood that the invention is not so limited. Namely, the device 100 can have an integral or single-piece monolithic construction.


It should be evident that the device 100 has a configuration such that it can be utilized in a manner similar to that of the previous embodiment, as depicted in FIG. 4 herein.


The device of the present invention, and components thereof, can be made of any suitable material, such as, metal, wood, plastic, etc. In a preferred embodiment, the device can be made of an injection molded plastic material to simplify production and reduce costs. Similarly, in one optional embodiment, a control solution is absorbed onto a carrier layer of porous absorbent material that is placed into a reservoir in the control wand then sealed with a frangible environmental seal, such as a thin aluminum foil. It is also understood that the control material could be placed directly into the cavity in the control wand and sealed without a carrier. Instead of a wand-type delivery device of the type previously described, the control material delivery device could come in the form of a:

    • blister filled with control material. The foil sealed blister could still be used to initiate the test as described herein
    • gel-cap filled with control material similar to gel-caps used to delivery drugs such as OTC pain reducers, or
    • any other method of containing and automatically dispensing an appropriate dosage of control material.


An example of the above-mentioned alternative control material delivery devices is illustrated in FIGS. 9-13. This illustrated therein, a plurality of such devices 150 can be coupled or packaged together. Each individual control material delivery device 152 is separable by any suitable mechanism. For instance, the plurality of devices 150 can be provided with frangible areas 154 for separating the individual devices 152 from one another. The frangible areas 154 can be provided by any suitable mechanism, such as scoring or other weakening of the material in these areas.


Each individual control material delivery device 152 can be provided in any suitable form. According to the illustrated embodiment, each device 152 can comprise a body 156. The body 156 can take any suitable form. According to the illustrated embodiment, the body 156 is in the form of a strip-like member. The body 156 can be formed from any suitable material, such as a plastic, fibrous material, or composite.


Attached to the body 156 is a reservoir 158. The reservoir can be provided with any suitable construction. For example, the reservoir can be configured to mate with an opening provided in an analyte monitor or meter, for example, in the manner previously described in connection with the description of FIG. 4. Each reservoir 158 is configured to receive a control material 160 therein. Each reservoir 158 may also be provided with a seal 162 to maintain that control material 160 within the reservoir 158. The seal 162 can take any suitable form. For example, the seal 162, according to the illustrated embodiment, comprises a pierceable member such as a thin metal foil. Thus, the seal 162 may optionally be provided with a construction which is pierceable by a member such as a hollow needle, as previously described in connection with the embodiment depicted in FIG. 4. Each device 152 may also be provided with a flange-like member 164 which is also attached to the body 156 of the device 152. The flange-like member 164 provides rigidity and support to the reservoir 158, and facilitates attachment thereof to the body 156.


The flange-like member 164 may also include a backing 166 which is not pierceable. Thus, for example, the backing 166 is not pierceable by a hollow needle. This construction of the backing 166 can be provided to protect the fingers of a user when the reservoir 158 is inserted into a meter or monitor, which includes a piercing element, such as a hollow needle, which is used to access the control material 160 within the reservoir 158.


Devices constructed according to further alternative embodiments of the present invention are depicted in FIGS. 14-30B. These devices have a construction and functionality which is similar to that of the previously described embodiments. Therefore, where a feature of the alternative embodiments finds a corresponding or feature in common with the previously described embodiments, they have been given similar reference numerals (e.g., 113 and 213). Therefore, reference is made to the previously described embodiments for supplemental description of these previously described features.


The devices and methods according to the embodiments depicted in FIGS. 14-30B have certain features in common. For instance, according to these alternative embodiments, the device 200 can possess a single piece construction, as opposed to a two-piece construction described according to other embodiment of the present invention. Each of these embodiments also may possess a reservoir constructed to retain a control material in flowable or liquid form, the provision of a porous or absorbent material as a carrier is not required, however, may be present according to further optional embodiments. These embodiments also possess a flexible neck construction which facilitates alignment and usage of the device, in particular by people with diabetes. The devices of these embodiments can also be made of any suitable material, such as, metal, wood, plastic, etc. According to one option, the device can be made of an injection molded plastic material to simplify production and reduce costs.


As illustrated, for example, in FIGS. 14-17, the first portion 212 of the device 200 is provided with a configuration which facilitates handling by a user. This is particularly important when the device 200 is intended for use with blood glucose monitors. This is because people with diabetes can lack tactile dexterity. Thus, the first portion 212 of the device 200 can be provided with any suitable form which facilitates grasp by a user.


According to the illustrated embodiment, the first portion 212 comprises a flattened relatively wide paddle-like shape. The paddle-like shape includes facing surfaces 213 which are contoured in an hourglass type manner such that the second portion 212 is provided with a cross-section that is relatively thin toward the middle, and wider towards its ends (FIGS. 15-16). The first portion 212 may optionally be provided with a feature that reduces slippage. For example, according to the nonlimiting illustrated embodiment, the first portion 212 is provided with a series of raised projections or ribs 215. Alternative features, such as a high friction surface coating or material disposed on all or a portion of surfaces 213 and/or ribs 215 may also be provided.


The device 200 may further include a second portion 214 with a flexible neck construction 230. The flexible neck 230 facilitates usage of the device by permitting relative movement between the first portion 212 and second portion 214 of the device. The flexible neck 230 can facilitate use of the device 200 in connection with mating the body 224 with an opening in a meter. The relative movement between the first portion 212 and the second portion 214 facilitates keeping the flanged 222 body 224 pressed flat against the opening, thus improving the ability to form a seal therewith. The flexible neck 230 may possess any suitable construction permits this desired relative movement. Thus, the flexible neck may simply comprise a relatively thin neck of flexible material, or other alternative configurations. According to the illustrated examples, the flexible neck 230 comprises a series of sections 231 interconnected by one or more thin flexible necks 232.


The second portion 214 of the device 200 can define a reservoir 216, which houses a control material 218, as described in connection with the previous embodiments. Optionally, the control material 218 can contain one or more target analytes having a known and/or predetermined concentration and can be in liquid or flowable form as illustrated in, for example, FIGS. 16-17. The reservoir 216 can be sealed by a corresponding closure or seal 220. The second portion 214 further comprises a flanged 222 body 224, configured in a manner similar to that of the previously described embodiment.


According to certain alternative embodiments, the device 200 can include one or more features which allow the user to urge the control material out of the device so as to deliver it to its intended location. A number of such features are contemplated, including the use of positive and/or negative pressures. According to one nonlimiting, specific example, as illustrated in FIG. 18, the first portion 212 of the device 200 can comprise a hollow interior region 260. Further, the second portion 214 of the device may also comprise a hollow region 262, which is preferably in communication with the first hollow region 260. Thus, the user is able to grasp the handle 213 and squeeze in the direction of the horizontal arrows appearing in FIG. 18. This compression of hollow region 260 forces any air, or other fluid, contained therein in the direction of the vertical arrow. The forced fluid then travels through the second hollow region 262 and into the reservoir 216, where it then acts to force the control material 218 out the opening of the reservoir 216. It should be evident that any of the previously or subsequently described embodiments can be modified in a suitable manner, similar to that described above, to provide the same optional functionality.


As mentioned above, in the embodiments depicted in FIGS. 14-24 the first portion 212 in the second portion 214 are integrally formed or comprise a single-piece monolithic construction. However, the invention is not so limited and can be formed in multiple parts that are either permanently or releasably connected together.


It should be evident that the device 200 has a configuration such that it can be utilized in a manner similar to that described in connection with the previous embodiments.


The device 200 illustrated in FIGS. 19-20 has the same features as the device 200 described above. As illustrated in FIGS. 19-20, the device 200 according to this alternative embodiment possesses a gasket or seal 240 disposed about the body 224 and abutting the flange 222. The gasket 240 can be formed from any suitable material, natural or synthetic. For example, the gasket 240 can be formed from foam, rubber, cork material, or a composite. The gasket 240 can be a separate component that is fitted over the body. When formed as a separate component, the gasket can be held in place by friction or by a suitable adhesive. Alternatively, the gasket 240 can be co-molded with the device 200 so as to be unified therewith. The gasket 240 enhances a seal formed between the flanged 222 body 224 when the device 200 is used in conjunction and mated with an opening of a meter, as will be described in greater detail herein.


The device 200 illustrated in FIGS. 21-22 has the same features as the device 200 described above. As illustrated in FIGS. 21-22, the device 200 according to this alternative embodiment possesses an alternative closure 250 for the reservoir 216. The alternative closure 250 can have any suitable construction. According to the optional illustrated embodiment the closure 250 comprises a handle or hinge 252 connected to the flanged 222 body 224. The hinge 252 can be connected in any suitable fashion. According to the illustrated embodiment, the hinge 252 is integrally formed with the flanged 222 body 224, such as by molding. Alternatively, the hinge may be separately formed and secured in place by adhesive, heat welding, ultrasonic welding or other suitable technique. The hinge may also include a ring or collar that fits around the body 224 to secure the hinge 252 in place. The closure 250 may further include a cap portion 254 that mates with reservoir 216 opening forming a seal therewith to contain the control material 218 contained therein (FIG. 16). According to one optional embodiment, the cap portion 254 can be pressed down and lifted up by a user to form a re-sealable closure. Alternatively, the cap portion 254 can be secured in place to the flanged 222 body 224 by adhesive, heat welding, ultrasonic welding, or other suitable technique. The cap portion may comprise a frangible portion 256. The frangible portion 256 can be constructed so that it is pierceable by a lancet, needle, or similar modality.


The device 200′ illustrated in FIGS. 23-24 can share any combination or all of the same features as the device 200 of the previously described embodiments. The main distinction is that device 200′ has two second portions 214A, 214B, each with a flexible neck construction 230A, 230B optionally provided with a construction previously described herein (components of the second portion 214A are labeled as in previous figures with “A” added to each label, and the components of the second portion 214B are labeled as in previous figures with “B” added to each label). Each second portion 214A, 214B of the device 200′ defines a reservoir 216A, 216B which houses a control material 218A, 218B. The control material 218A, 218B can be essentially the same, thus providing the ability to perform at least two similar control tests with the same device 220′. As previously described, the control material may contain one or more target analyte(s). Alternatively, the control material 218A can differ from the control material 218B in one or more respects. For example, the first control material may contain a relatively lower concentration of a target analyte, while the second control material may contain a relatively higher concentration of the target analyte, thus providing a single device 200′ with the ability to conduct a control test for both low and high analyte concentration ranges to ensure even greater accuracy of a meter or other measuring device. According to a further option, the control materials 218A, 218B can be used to perform a control test for at least two different target analytes. Thus, the first control material 218A can have a known concentration of a first analyte, while the second control material 218B can have a known concentration of a second analyte. The reservoirs 216A, 216B can be sealed by a corresponding closure or seal 220A, 220B, as illustrated. Alternatively, the closure can be constructed as illustrated and described above in connection with FIGS. 21-22. The second portions 214A, 214B can have either the same type of closure or seal, or different types of closures/seals.


According to further optional embodiments of the present invention, any of the previously or subsequently described embodiments can be modified so as to include an alternative reservoir construction, an example of which being illustrated in the embodiments depicted in FIGS. 25-26. As illustrated therein, the second portion 214 of the device includes a modified reservoir 216′. The modified reservoir 216′ can be generally characterized as being in the form of a separable multi-piece construction. Such a construction can provide certain advantages. For example, the separable reservoir component containing the control material can be in the form of a cartridge which can be inserted into a reusable handle portion constituting the remainder of the device. Thus, once the control test has been conducted, the separable reservoir component containing control material can be removed and discarded appropriately. Such a construction may provide advantages in terms of cost and convenience, as well as significantly reducing waste due to the reusability of the handle portion. Further, the separable reservoir component containing the control material can be formed of a material which is different in nature than that of the handle portion into which it is inserted. For instance, the separable reservoir component can be formed from a relatively low moisture vapor transmission rate (LMVTR) material. Thus, the control material is kept in a more stable manner that would be possible using a higher moisture vapor transmission rate material. To the extent that the LMVTR material is more costly than a relatively higher moisture vapor transmission rate material, cost savings can be obtained through the above-mentioned modified reservoir construction.


The above noted concepts can be executed in any suitable manner. According to the nonlimiting illustrated embodiment, the modified reservoir portion 216′ comprises a lower member 270 defining a recess 272 therein. Received within a recess 272 is a separable reservoir component 274 containing the control material 218. The separable component may be closed by a frangible seal 220, as previously described, As noted above, this separable component 274 can be formed of any suitable material, such as a LMVTR plastic material. The separable component 274 can be retained within the recess 272 in any suitable fashion. Contemplated alternatives include adhesives, fasteners, and frictional retention. According to the illustrated embodiments, the separable component 274 is retained within the recess 272 by plurality of interacting frictional detents 276, 278.


Further aspects of the invention involves analyte testing/monitoring devices and methods including the devices (e.g., 100, 200, 200′) of the type described above in conjunction with an integrated analyte monitor or meter. The integrated monitor or meter optionally being capable of one or more of the following:

    • extracting the control material
    • transporting the control material to an analysis site within the integrated monitor (e.g., as described in several of the integrated meter documents incorporated herein by reference)
    • analyzing the control material to determine the concentration of the analyte contained in the fluid
    • analyzing the control to determine whether the sample is a body fluid or a control material
    • comparing the result of the control test against a control calibration value, which may be read off a barcode, RFID, or similar device and/or stored in a memory of the monitor or meter, and
    • displaying the result of the control test as a simple-to-interpret pass or fail result through simple audible/visual signals.


To complete the described steps automatically the analyte monitor should also have the capability of gathering calibration information automatically, such as from an analyte concentration measuring and analysis mechanism contained with the device. If analysis site(s) is/are contained within a single strip or multi-test cartridge CR, as illustrated in FIG. 27, the calibration information for the analyte concentration measuring and analysis mechanism(s) could be delivered to the meter or monitor M via a bar code BR, RFID chip CH or other mechanism.


One advantage of the invention is automated detection and marking of a control test to distinguish that test from, for example, a test involving a sample of body fluid. This can be accomplished by several methods; one method of identifying a control test is described as follows. The control material can be designed such that it reacts with the analysis site in a manner distinguishable from the reaction with a bodily fluid. For example, the viscosity of the control material can be so different, either lower or higher than the tested body fluid, that the rate of reaction or sample delivery can be used to distinguish control material from body fluid. Specifically, glucose monitors typically have stated hematocrit ranges that are acceptable for use with the device. As hematocrit increases the viscosity of blood also increases. The analysis site and method could be designed in such a manner that the rate of reaction is inversely related to hematocrit (higher hematocrit=slower reaction). This has been described, for example, in US 2006/0281187, the entire contents of which is incorporated herein by reference. To accomplish this, the control material used within the analysis site could be contained in a porous material. The size of the pores in the material can be used to control the rate of reaction. The control fluid can be designed such that its viscosity is lower than the equivalent viscosity of the lowest allowable hematocrit level. Therefore as the analysis is completed within the integrated monitor the rate of reaction can be used to identify control material tests.


Another method of identifying a control sample versus a body fluid sample involves adding identifying markers to the control material. For example, control material could be identified by optical detection by adding color within the detection wavelength such that a color change of an order of magnitude higher than physiologically possible given the kinetics of the assay occurs nearly instantaneously. The degree of color added via a dye or other colored means is enough to detect via this method, but not so much as to reduce the dynamic detection range of the system so that the proper level of analyte detection in the control material can correctly indicate system analyte recovery status as “Pass” or “Fail” through clear audible and/or visual signals. Another similar option that may be implemented is to provide the control material with a chemical marker that initially reacts with the analysis site to produce an initial spike in color indicating to the meter the presence of control solution. The initial color spike can be designed to quickly disappear. Subsequently, the analysis site reacts with the analyte(s) in a manner that can be read and interpreted to determine the concentration thereof.


Other similar methods of observing the time rate of change of the analysis site (reagent) are also comprehended, i.e., very slow reaction, or reactions proceeding along known value vs. time plots, etc.


According to further alternative embodiments, the automated determination of a control solution test can be accomplished using algorithms executed by the electronic components within a monitor or meter.


A method performed according to the principles of one embodiment of the present invention includes one or more of the steps in FIGS. 27 and 28A-28D:\


Step 1: Provide calibration information to the monitor or device (e.g., FIG. 27 as described above).


Step 2: Use control material applicator (100, 200, 200′) to deliver a dose of control material to monitor or device (M) (FIG. 28A). Note: The integrated monitor can optionally detect the presence of a “finger,” in this case the control wand (100, 200. 200′), and automatically lances the closure (20, 120, 220, 256) and transports the control material (18, 118, 218) (e.g., FIG. 4).


Step 3: Integrated monitor analyzes the control material and determines that sample is a control test as indicated by any suitable symbol, such as the “check-mark” symbol on LCD (FIG. 28B). Alternatively, the monitor may provide an audible signal in place of, or in addition to, the symbol.


Step 4a: Control material is analyzed and its analyte concentration value is displayed (e.g., 100 mg/dL) and compared against stored calibration values. In this example, the value is within the expected range and device displays any suitable symbol, such as the “check” indicating “pass” (FIG. 28C). Alternatively, the monitor may provide an audible signal in place of, or in addition to, the symbol.


Step 4b: Control material is analyzed, the measured analyte concentration displayed and found to be outside of the expected range. In this case, the monitor indicates a failed test by displaying any suitable symbol, such as crossed-out check mark. Alternatively, the monitor may provide an audible signal in place of, or in addition to, the symbol. Note the “i” symbol indicates that user should look at manual to see how to address the failed test (FIG. 28D).


An alternative method performed according to a further optional embodiment is illustrated in FIGS. 27 and 29A-29D, and is described as follows.


Step 1: Provide calibration information to the monitor or device (e.g., FIG. 27 as described above).


Step 2: Use control material applicator (100, 200, 200′) to deliver a dose of control material (18, 118, 218) to monitor or device (M) (FIG. 29A). Note: The integrated monitor can optionally detect the presence of a “finger,” in this case the control wand (100, 200, 200′), and automatically lances the closure (20, 120, 220, 256) and transports the control material (e.g., FIG. 4). The monitor M can optionally signal the user when the applicator can be removed from the opening.


Step 3: Integrated monitor analyzes the control material and determines that sample is a control test as indicated by any suitable symbol, such as the “check-mark” symbol on LCD (e.g., FIG. 29B). Alternatively, the monitor may provide an audible signal in place of, or in addition to, the symbol.


Step 4a: Control material is analyzed and its analyte concentration value is compared against stored calibration values. In this example, the value is within the expected range and device displays any suitable symbol, such as the “check” and a “P” indicating “pass” (FIG. 29C). Alternatively, the monitor may provide an audible signal in place of, or in addition to, the symbol. Additional and/or alternative visual and audible signals are contemplated. For example, the meter M can play a recorded spoken “pass” message. Note that unlike the previous embodiment, the concentration of analyte measured by the device is not displayed. It has been found that some users can become confused by the display of a concentration value and mistakenly assume it is a reading of the concentration of analyte in a sample of the user's body fluid, and engage in treatment (e.g., insulin dosage) based on this misunderstanding of the concentration value displayed by the meter M. This embodiment avoids such opportunity for misinterpretation.


Step 4b: Control material is analyzed, the measured analyte concentration value is compared by the meter M against stored control or calibration values and found to be outside of the expected range. In this case the monitor displays a fail test. Any suitable symbol, such as the symbol indicated by the crossed check mark and “F,” indicative of a failed control test. Additional and/or alternative visual and audible signals are contemplated. For example, the meter M can play a recorded spoken “fail” message. Note the “i” symbol indicates that user should look at manual to see how to address the failed test (FIG. 29D).


It should be understood that the present invention is not limited to use of the devices (100, 200, 200′) described herein with a particular type of meter or device. The present invention contemplates devices and methods that do not rely upon an integrated type meter or monitor. For example, many commercially available blood glucose monitoring systems include a lancing device, test strips and meter, one or more of which are separate components of the system. An arrangement and a control testing method performed according to an alternative embodiment of the present invention is illustrated in FIGS. 30A-30B. As illustrated therein, a device of the type described herein (100, 200, 200′) contains a control material C. The control material C can have any suitable form or composition as previously described herein (18, 118, 218). The control material C is accessed by any suitable measure, such as by using a separate lancing device L that is commonly part of non-integrated blood glucose monitoring systems to pierce the closure or seal of the reservoir containing the control material C (FIG. 30A). A test strip S used for analyzing the concentration of a target analyte in a sample of body fluid by know techniques is inserted into a non-integrated meter M2. Using the device (100, 200, 200′) the control material C is applied to a test strip S in a manner similar to how the user would introduce a sample of body fluid, such as blood obtained from a finger prick. The control material is then analyzed by the strip S and meter M2 in any suitable manner in order to verify whether or not the measured concentration of analyte in the control material C is within a tolerable expected range, and the results presented to the user, This can be done in any suitable manner, such as described herein in connection with previous embodiments.


According to one optional modification of the above described embodiment of FIGS. 30A-30B, instead of using the device (100, 200, 200′) to apply the control material C directly to the test strip S, the control may be applied directly to the surface of a finger. The test strips is then brought into communication with the control material C on the finger, and is transported therein for analysis. This procedure more closely mimics a finger prick test using such non-integrated meters, and thus may be easier for the user to practice due to the familiarity of steps.


Numbers expressing quantities of ingredients, constituents, reaction conditions, and so forth used in this specification are to be understood as being modified in all instances by the term “about”. Notwithstanding that the numerical ranges and parameters setting forth, the broad scope of the subject matter presented herein are approximations, the numerical values set forth are indicated as precisely as possible. Any numerical value, however, may inherently contain certain errors necessarily resulting from the standard deviation found in their respective measurement techniques. None of the elements recited in the appended claims should be interpreted as invoking 35 U.S.C. §112, ¶6, unless the term “means” is explicitly used.


Although the present invention has been described in connection with preferred embodiments thereof, it will be appreciated by those skilled in the art that additions, deletions, modifications, and substitutions not specifically described may be made without departing from the spirit and scope of the invention as defined in the appended claims.

Claims
  • 1. A device comprising: a first portion configured to be grasped by a hand of a user; anda second portion comprising: a reservoir containing a first control material, wherein the control material comprises a target analyte of a known or a predetermined concentration; anda flexible neck configured to permit relative movement between the first portion and the reservoir, wherein the flexible neck comprises a first narrow neck region, a second narrow neck region, and an enlarged neck region between the first and second narrow neck regions.
  • 2. The device of claim 1, further comprising a frangible seal which contains the control material within the reservoir, and shields the control material from exposure to the environment.
  • 3. The device of claim 1, wherein the control material comprises a control liquid or solution.
  • 4. The device of claim 3, wherein the control material comprises an absorbent material upon which the control liquid or solution is absorbed.
  • 5. The device of claim 1, wherein the first portion is in the form of a flattened shape.
  • 6. The device of claim 5, wherein the first portion has a cross-section which is relatively thin at its middle, and relatively wider at its ends.
  • 7. The device of claim 6, further comprising a slippage reducing feature.
  • 8. The device of claim 7, wherein the slippage reducing feature comprises one or more ribs disposed on the first portion.
  • 9. The device of claim 1, wherein the first portion and the second portion are formed as separate components which are joined together.
  • 10. The device of claim 1, wherein the first and second portions are integrally formed.
  • 11. The device of claim 10, wherein the first and second portions are part of a one-piece monolithic structure.
  • 12. The device of claim 2, wherein the frangible seal comprises a pierceable foil.
  • 13. The device of claim 2, wherein the frangible seal comprises a hinge and a cap portion configured to mate with and seal the reservoir.
  • 14. The device of claim 1, further comprising a third portion defining a reservoir containing a second control material.
  • 15. The device of claim 14, wherein the first and second control materials are substantially the same.
  • 16. The device of claim 14, wherein the first and second control materials are different.
  • 17. The device of claim 1, wherein the control material further comprises at least one marker indicative of the presence of the control material.
  • 18. The device of claim 17, wherein the marker is composed to produce a color change possessing a degree of magnitude such that it is indicative of the presence of the control material.
  • 19. The device of claim 18, wherein the marker comprises a dye.
  • 20. The device of claim 17, wherein the marker is composed to produce a temporary color change indicative of the presence of the control material.
CROSS-REFERENCE TO RELATED APPLICATIONS

The present application claims priority to U.S. patent application No. 61/358,791, filed Jun. 25, 2010, and U.S. patent application Ser. No. 61/265,247, filed Nov. 30, 2009.

US Referenced Citations (443)
Number Name Date Kind
842690 Oswalt Jan 1907 A
D137874 Partridge May 1944 S
2749797 Harks Mar 1950 A
3092465 Adams, Jr. Jun 1963 A
3310002 Wilburn Mar 1967 A
3620209 Kravitz Nov 1971 A
3623475 Sanz et al. Nov 1971 A
3626929 Sanz et al. Dec 1971 A
3630957 Rey Dec 1971 A
D223165 Komendat Mar 1972 S
3723064 Liotta Mar 1973 A
3741197 Sanz et al. Jun 1973 A
3961898 Neeley et al. Jun 1976 A
4014328 Cluff et al. Mar 1977 A
4042335 Clement Aug 1977 A
4057394 Genshaw Nov 1977 A
4109655 Chacornac Aug 1978 A
4254083 Columbus Mar 1981 A
4258001 Pierce et al. Mar 1981 A
4260257 Neeley et al. Apr 1981 A
4289459 Neeley et al. Sep 1981 A
4311792 Avery Jan 1982 A
4321397 Nix et al. Mar 1982 A
4350762 DeLuca et al. Sep 1982 A
4394512 Batz Jul 1983 A
4414975 Ryder et al. Nov 1983 A
4416279 Lindner et al. Nov 1983 A
4418037 Katsuyama et al. Nov 1983 A
4422941 Vaughan, Jr. et al. Dec 1983 A
4429700 Thees et al. Feb 1984 A
4627445 Garcia et al. Dec 1986 A
4637403 Garcia et al. Jan 1987 A
4637406 Guinn et al. Jan 1987 A
4653513 Dombrowski Mar 1987 A
4661319 Lape Apr 1987 A
4702261 Cornell et al. Oct 1987 A
4711250 Gilbaugh, Jr. et al. Dec 1987 A
4737458 Batz et al. Apr 1988 A
4749655 Monthony et al. Jun 1988 A
4767415 Duffy Aug 1988 A
4774192 Terminiello et al. Sep 1988 A
4790979 Terminiello et al. Dec 1988 A
4794926 Munsch et al. Jan 1989 A
4815843 Tiefenthaler et al. Mar 1989 A
4829470 Wang May 1989 A
4846785 Cassou et al. Jul 1989 A
4887306 Hwang et al. Dec 1989 A
4920977 Haynes May 1990 A
4930525 Palestrant Jun 1990 A
4935346 Phillips Jun 1990 A
4953552 De Marzo Sep 1990 A
4966646 Zdeblick Oct 1990 A
4995402 Smith Feb 1991 A
5029583 Meserol Jul 1991 A
5049487 Phillips et al. Sep 1991 A
5050617 Columbus et al. Sep 1991 A
5059394 Phillips et al. Oct 1991 A
5077199 Basagni et al. Dec 1991 A
5094943 Siedel et al. Mar 1992 A
5116759 Klainer et al. May 1992 A
5131404 Neeley et al. Jul 1992 A
5141868 Shanks et al. Aug 1992 A
5145565 Kater et al. Sep 1992 A
5146437 Boucheron Sep 1992 A
5153416 Neeley Oct 1992 A
5164575 Neeley et al. Nov 1992 A
5166498 Neeley Nov 1992 A
5174291 Schoonen et al. Dec 1992 A
5176632 Bernardi Jan 1993 A
5179005 Phillips et al. Jan 1993 A
5183741 Arai et al. Feb 1993 A
5196302 Kidwell Mar 1993 A
5208163 Charlton et al. May 1993 A
5213966 Vuorinen et al. May 1993 A
5217480 Haber et al. Jun 1993 A
5218966 Yamasawa Jun 1993 A
5223219 Subramanian et al. Jun 1993 A
5234818 Zimmermann et al. Aug 1993 A
5241969 Carson et al. Sep 1993 A
5251126 Kahn et al. Oct 1993 A
D341848 Bigelow et al. Nov 1993 S
5266266 Nason Nov 1993 A
5275159 Griebel Jan 1994 A
5278079 Gubinski et al. Jan 1994 A
5288646 Lundsgaard et al. Feb 1994 A
5299571 Mastrototaro Apr 1994 A
5301686 Newman Apr 1994 A
5302513 Miike et al. Apr 1994 A
5304468 Phillips et al. Apr 1994 A
5306623 Kiser et al. Apr 1994 A
5308767 Terashima May 1994 A
5320607 Ishibashi Jun 1994 A
5354537 Moreno Oct 1994 A
5360595 Bell et al. Nov 1994 A
5368047 Suzuki et al. Nov 1994 A
5383512 Jarvis Jan 1995 A
5390671 Lord et al. Feb 1995 A
5399316 Yamada Mar 1995 A
5401110 Neeley Mar 1995 A
5402798 Swierczek et al. Apr 1995 A
5441513 Roth Aug 1995 A
5451350 Macho et al. Sep 1995 A
5458140 Eppstein et al. Oct 1995 A
5460777 Kitajima et al. Oct 1995 A
5460968 Yoshida et al. Oct 1995 A
5482473 Lord et al. Jan 1996 A
5506200 Hirschkoff et al. Apr 1996 A
5507288 Bö{umlaut over ( )}cker et al. Apr 1996 A
5508200 Tiffany et al. Apr 1996 A
5510266 Bonner et al. Apr 1996 A
5514152 Smith May 1996 A
5568806 Cheney, II et al. Oct 1996 A
5569287 Tezuka et al. Oct 1996 A
5575403 Charlton et al. Nov 1996 A
5577499 Teves Nov 1996 A
5582184 Erickson et al. Dec 1996 A
5586553 Halili et al. Dec 1996 A
5591139 Lin et al. Jan 1997 A
5611809 Marshall et al. Mar 1997 A
5624458 Lipscher Apr 1997 A
5630986 Charlton et al. May 1997 A
5632410 Moulton et al. May 1997 A
5636632 Bommannan et al. Jun 1997 A
5647851 Pokras Jul 1997 A
5658515 Lee et al. Aug 1997 A
5660791 Brenneman et al. Aug 1997 A
5676850 Reed et al. Oct 1997 A
5680858 Hansen et al. Oct 1997 A
5681484 Zanzucchi et al. Oct 1997 A
5682233 Brinda Oct 1997 A
5697901 Eriksson Dec 1997 A
5701181 Boiarski et al. Dec 1997 A
5701910 Powles et al. Dec 1997 A
5705018 Hartley Jan 1998 A
5708787 Nakano et al. Jan 1998 A
5715417 Gardien et al. Feb 1998 A
5730753 Morita Mar 1998 A
5735273 Kurnik et al. Apr 1998 A
5736103 Pugh Apr 1998 A
5741211 Renirie et al. Apr 1998 A
5746217 Erickson et al. May 1998 A
5746720 Stouder, Jr. May 1998 A
5757666 Schreiber et al. May 1998 A
5759364 Charlton et al. Jun 1998 A
5766066 Ranniger Jun 1998 A
5771890 Tamada Jun 1998 A
5797693 Jaeger Aug 1998 A
5801057 Smart et al. Sep 1998 A
5807375 Gross et al. Sep 1998 A
5820570 Erickson et al. Oct 1998 A
5827183 Kurnik et al. Oct 1998 A
5840020 Heinonen et al. Nov 1998 A
5841126 Fossum et al. Nov 1998 A
5843692 Phillips et al. Dec 1998 A
5846837 Thym et al. Dec 1998 A
5854074 Charlton et al. Dec 1998 A
D403975 Douglas et al. Jan 1999 S
5855801 Lin et al. Jan 1999 A
5856195 Charlton et al. Jan 1999 A
5858194 Bell Jan 1999 A
5866281 Guckel et al. Feb 1999 A
5871494 Simons et al. Feb 1999 A
5879310 Sopp et al. Mar 1999 A
5879326 Godshall et al. Mar 1999 A
5879367 Latterell et al. Mar 1999 A
5891053 Sesekura Apr 1999 A
5893870 Talen et al. Apr 1999 A
5911711 Pelkey Jun 1999 A
5911737 Lee et al. Jun 1999 A
5912139 Iwata et al. Jun 1999 A
5925021 Castellano et al. Jul 1999 A
5928207 Pisano et al. Jul 1999 A
5930873 Wyser Aug 1999 A
5938679 Freeman et al. Aug 1999 A
5945678 Yanagisawa Aug 1999 A
5951492 Douglas et al. Sep 1999 A
5951493 Douglas et al. Sep 1999 A
5954685 Tierney Sep 1999 A
5962215 Douglas et al. Oct 1999 A
5968760 Phillips et al. Oct 1999 A
5968765 Grage et al. Oct 1999 A
5971941 Simons et al. Oct 1999 A
5972294 Smith et al. Oct 1999 A
5986754 Harding Nov 1999 A
5989409 Kurnik et al. Nov 1999 A
5993189 Mueller et al. Nov 1999 A
6001067 Shults et al. Dec 1999 A
6005545 Nishida et al. Dec 1999 A
6010463 Lauks et al. Jan 2000 A
6010519 Mawhirt et al. Jan 2000 A
6014135 Fernandes Jan 2000 A
6014577 Henning et al. Jan 2000 A
6023629 Tamada Feb 2000 A
6027459 Shain et al. Feb 2000 A
6030827 Davis et al. Feb 2000 A
6032059 Henning et al. Feb 2000 A
6036924 Simons et al. Mar 2000 A
6041253 Kost et al. Mar 2000 A
6050988 Zuck Apr 2000 A
6056701 Duchon et al. May 2000 A
6056734 Jacobsen et al. May 2000 A
6058321 Swayze et al. May 2000 A
6059815 Lee et al. May 2000 A
6061128 Zweig et al. May 2000 A
6063039 Cunningham et al. May 2000 A
6071294 Simons et al. Jun 2000 A
6077660 Wong et al. Jun 2000 A
6080116 Erickson et al. Jun 2000 A
6083196 Trautman et al. Jul 2000 A
6086544 Hibner et al. Jul 2000 A
6090790 Eriksson Jul 2000 A
6091975 Daddona et al. Jul 2000 A
6093156 Cunningham et al. Jul 2000 A
6097831 Wieck et al. Aug 2000 A
6099484 Douglas et al. Aug 2000 A
6100107 Lei et al. Aug 2000 A
6102933 Lee et al. Aug 2000 A
6103033 Say et al. Aug 2000 A
6103197 Werner Aug 2000 A
6106751 Talbot et al. Aug 2000 A
6118126 Zanzucchi Sep 2000 A
6120676 Heller et al. Sep 2000 A
6123861 Santini, Jr. et al. Sep 2000 A
6126899 Woudenberg et al. Oct 2000 A
6132449 Lum et al. Oct 2000 A
6139562 Mauze et al. Oct 2000 A
6142939 Eppstein et al. Nov 2000 A
6152942 Brenneman et al. Nov 2000 A
6162639 Douglas Dec 2000 A
6175752 Say et al. Jan 2001 B1
6176865 Mauze et al. Jan 2001 B1
6183434 Eppstein et al. Feb 2001 B1
6183489 Douglas et al. Feb 2001 B1
6187210 Lebouiz et al. Feb 2001 B1
6192891 Gravel et al. Feb 2001 B1
6200296 Dibiasi et al. Mar 2001 B1
6206841 Cunningham et al. Mar 2001 B1
6214626 Meller et al. Apr 2001 B1
6219574 Cormier et al. Apr 2001 B1
6228100 Schraga May 2001 B1
6230051 Cormier et al. May 2001 B1
6231531 Lum et al. May 2001 B1
6241862 McAleer et al. Jun 2001 B1
6242207 Douglas et al. Jun 2001 B1
6245215 Douglas et al. Jun 2001 B1
6251083 Yum et al. Jun 2001 B1
6251260 Heller et al. Jun 2001 B1
6254586 Mann et al. Jul 2001 B1
6255061 Mori et al. Jul 2001 B1
6256533 Yuzhakov et al. Jul 2001 B1
6268162 Phillips et al. Jul 2001 B1
6271045 Douglas et al. Aug 2001 B1
6272364 Kurnik Aug 2001 B1
6283926 Cunningham et al. Sep 2001 B1
6289230 Chaiken et al. Sep 2001 B1
6298254 Tamada Oct 2001 B2
6299578 Kurnik et al. Oct 2001 B1
6309351 Kurnik et al. Oct 2001 B1
D450711 Istvan et al. Nov 2001 S
6312612 Sherman et al. Nov 2001 B1
6312888 Wong et al. Nov 2001 B1
6322808 Trautman et al. Nov 2001 B1
6329161 Heller et al. Dec 2001 B1
6331266 Powell et al. Dec 2001 B1
6332871 Douglas et al. Dec 2001 B1
6334856 Allen et al. Jan 2002 B1
6350273 Minagawa et al. Feb 2002 B1
6352514 Douglas et al. Mar 2002 B1
6356776 Berner et al. Mar 2002 B1
6358265 Thorne, Jr. et al. Mar 2002 B1
6364890 Lum et al. Apr 2002 B1
6375626 Allen et al. Apr 2002 B1
6375627 Mauze et al. Apr 2002 B1
6379969 Mauze et al. Apr 2002 B1
6391005 Lum et al. May 2002 B1
6409679 Pyo Jun 2002 B2
6428664 BhulLar et al. Aug 2002 B1
6449608 Morita et al. Sep 2002 B1
6455324 Douglas Sep 2002 B1
6500134 Cassone Dec 2002 B1
6520973 McGarry Feb 2003 B1
6530892 Kelly Mar 2003 B1
6537243 Henning et al. Mar 2003 B1
6540675 Aceti et al. Apr 2003 B2
6544475 Douglas et al. Apr 2003 B1
6555061 Leong et al. Apr 2003 B1
6558624 Lemmon et al. May 2003 B1
6579690 Bonnecaze et al. Jun 2003 B1
6602205 Erickson et al. Aug 2003 B1
6612111 Hodges et al. Sep 2003 B1
6616616 Fritz et al. Sep 2003 B2
6626874 Duchamp Sep 2003 B1
6656167 Numao et al. Dec 2003 B2
6679852 Schmelzeisen-Redeker et al. Jan 2004 B1
6706000 Perez et al. Mar 2004 B2
6706049 Moerman Mar 2004 B2
6706159 Moerman et al. Mar 2004 B2
6740800 Cunningham May 2004 B1
6748275 Lattner et al. Jun 2004 B2
6753187 Cizdziel et al. Jun 2004 B2
6766817 da Silva Jul 2004 B2
6793633 Douglas et al. Sep 2004 B2
6830669 Miyazaki et al. Dec 2004 B2
6836678 Tu Dec 2004 B2
6837858 Cunningham et al. Jan 2005 B2
6847451 Pugh Jan 2005 B2
6918404 Dias da Silva Jul 2005 B2
6919960 Hansen et al. Jul 2005 B2
6923764 Aceti et al. Aug 2005 B2
6936476 Anderson et al. Aug 2005 B1
6988996 Roe et al. Jan 2006 B2
7004928 Aceti et al. Feb 2006 B2
7011630 Desai et al. Mar 2006 B2
7025774 Freeman et al. Apr 2006 B2
7066586 Da Silva Jun 2006 B2
7066890 Lam et al. Jun 2006 B1
7141058 Briggs et al. Nov 2006 B2
7156809 Quy Jan 2007 B2
7192061 Martin Mar 2007 B2
D540343 Cummins Apr 2007 S
7223365 Freiherr Von Der Goltz May 2007 B2
7225008 Ward et al. May 2007 B1
7226461 Boecker et al. Jun 2007 B2
D551243 Young Sep 2007 S
7270970 Anderson et al. Sep 2007 B2
7297151 Boecker et al. Nov 2007 B2
7343188 Sohrab Mar 2008 B2
7344507 Briggs et al. Mar 2008 B2
7427377 Zanzucchi et al. Sep 2008 B2
D599373 Kobayashi et al. Sep 2009 S
D601578 Poulet et al. Oct 2009 S
7682318 Alden et al. Mar 2010 B2
7803123 Perez et al. Sep 2010 B2
7887494 Emery et al. Feb 2011 B2
D642191 Barnett et al. Jul 2011 S
20010001034 Douglas May 2001 A1
20010027328 Lum et al. Oct 2001 A1
20010053891 Ackley Dec 2001 A1
20020002326 Causey, III et al. Jan 2002 A1
20020002344 Douglas et al. Jan 2002 A1
20020004640 Conn et al. Jan 2002 A1
20020006355 Whitson Jan 2002 A1
20020016568 Lebel et al. Feb 2002 A1
20020020688 Sherman et al. Feb 2002 A1
20020023852 Mcivor et al. Feb 2002 A1
20020042594 Lum et al. Apr 2002 A1
20020052618 Haar et al. May 2002 A1
20020087056 Aceti et al. Jul 2002 A1
20020136667 Subramanian et al. Sep 2002 A1
20020137998 Smart et al. Sep 2002 A1
20020160520 Orloff et al. Oct 2002 A1
20020168290 Yuzhakov et al. Nov 2002 A1
20020169394 Eppstein et al. Nov 2002 A1
20020169411 Sherman et al. Nov 2002 A1
20020177761 Orloff et al. Nov 2002 A1
20020183102 Withers et al. Dec 2002 A1
20020188223 Perez et al. Dec 2002 A1
20020198444 Uchigaki et al. Dec 2002 A1
20030012693 Otillar et al. Jan 2003 A1
20030028087 Yuzhakov et al. Feb 2003 A1
20030028125 Yuzhakov et al. Feb 2003 A1
20030039587 Niermann Feb 2003 A1
20030083685 Freeman et al. May 2003 A1
20030083686 Freeman et al. May 2003 A1
20030116596 Terasawa Jun 2003 A1
20030135166 Gonnelli Jul 2003 A1
20030135333 Aceti Jul 2003 A1
20030153844 Smith et al. Aug 2003 A1
20030153900 Aceti et al. Aug 2003 A1
20030175987 Verdonk et al. Sep 2003 A1
20030206302 Pugh Nov 2003 A1
20030207441 Eyster et al. Nov 2003 A1
20030208113 Mault et al. Nov 2003 A1
20030211619 Olson et al. Nov 2003 A1
20030212344 Yuzhakov et al. Nov 2003 A1
20030212347 Sohrab Nov 2003 A1
20040010207 Flaherty et al. Jan 2004 A1
20040030353 Schmelzeisen-Redeker et al. Feb 2004 A1
20040049219 Briggs et al. Mar 2004 A1
20040059256 Perez Mar 2004 A1
20040073140 Douglas Apr 2004 A1
20040092842 Boecker et al. May 2004 A1
20040092995 Boecker et al. May 2004 A1
20040096959 Stiene et al. May 2004 A1
20040098009 Boecker et al. May 2004 A1
20040102803 Boecker et al. May 2004 A1
20040122339 Roe et al. Jun 2004 A1
20040132167 Rule et al. Jul 2004 A1
20040138588 Saikley et al. Jul 2004 A1
20040155084 Brown Aug 2004 A1
20040178218 Schomakers et al. Sep 2004 A1
20040186394 Roe et al. Sep 2004 A1
20040191119 Zanzucchi et al. Sep 2004 A1
20040202576 Aceti et al. Oct 2004 A1
20040209755 Moore et al. Oct 2004 A1
20040236251 Roe et al. Nov 2004 A1
20040238675 Banaszkiewicz et al. Dec 2004 A1
20050010134 Douglas et al. Jan 2005 A1
20050015020 LeVaughn et al. Jan 2005 A1
20050096686 Allen May 2005 A1
20050106713 Phan et al. May 2005 A1
20050159678 Taniike et al. Jul 2005 A1
20050187532 Thurau et al. Aug 2005 A1
20050202567 Zanzucchi et al. Sep 2005 A1
20050202733 Yoshimura et al. Sep 2005 A1
20050215872 Berner et al. Sep 2005 A1
20050215923 Wiegel Sep 2005 A1
20050244981 Frey et al. Nov 2005 A1
20050245844 Mace et al. Nov 2005 A1
20050277972 Wong et al. Dec 2005 A1
20060008389 Sacherer et al. Jan 2006 A1
20060036134 Tarassenko et al. Feb 2006 A1
20060117616 Jones et al. Jun 2006 A1
20060135873 Karo et al. Jun 2006 A1
20060155317 List Jul 2006 A1
20060178600 Kennedy et al. Aug 2006 A1
20060189908 Kennedy Aug 2006 A1
20060204399 Freeman et al. Sep 2006 A1
20060229533 Hoenes et al. Oct 2006 A1
20060241517 Fowler et al. Oct 2006 A1
20060257993 Mcdevitt et al. Nov 2006 A1
20060259102 Slatkine Nov 2006 A1
20060281187 Emery et al. Dec 2006 A1
20070017824 Rippeth et al. Jan 2007 A1
20070078313 Emery et al. Apr 2007 A1
20070078358 Escutia et al. Apr 2007 A1
20070083131 Escutia et al. Apr 2007 A1
20070149863 Padmanabhan et al. Jun 2007 A1
20070179404 Escutia et al. Aug 2007 A1
20070179405 Emery et al. Aug 2007 A1
20070255181 Alvarez-icaza et al. Nov 2007 A1
20070255302 Koeppel et al. Nov 2007 A1
20070274869 Rannikko Nov 2007 A1
20080046831 Imai et al. Feb 2008 A1
20080077048 Escutia et al. Mar 2008 A1
20080135559 Byrd Jun 2008 A1
20080194934 Ray et al. Aug 2008 A1
20090018426 Markle et al. Jan 2009 A1
20090156923 Power et al. Jun 2009 A1
20100021948 Lipman et al. Jan 2010 A1
20100095229 Dixon et al. Apr 2010 A1
20100185120 Sacherer et al. Jul 2010 A1
20120166090 Lipman et al. Jun 2012 A1
Foreign Referenced Citations (128)
Number Date Country
2 513 465 Aug 2004 CA
199 22 413 Nov 2000 DE
103 02 501 Aug 2004 DE
0 396-016 Nov 1990 EP
0 396-016 Nov 1990 EP
0 255-338 Feb 1998 EP
1 266-607 Dec 2002 EP
1 266-607 Dec 2002 EP
1 360-934 Nov 2003 EP
1 360-934 Nov 2003 EP
1 486-766 Dec 2004 EP
1 486-766 Dec 2004 EP
1 529-489 May 2005 EP
1 529-489 May 2005 EP
1 769-735 Apr 2007 EP
63-305841 Dec 1988 JP
3-63570 Mar 1991 JP
03093189 Apr 1991 JP
7-67861 Mar 1995 JP
7-213925 Aug 1995 JP
9-168530 Jun 1997 JP
9-313465 Sep 1997 JP
9-266889 Oct 1997 JP
9-294737 Nov 1997 JP
10-024028 Jan 1998 JP
10-318970 Dec 1998 JP
2000-126161 May 2000 JP
2000-168754 Jun 2000 JP
2000-254111 Sep 2000 JP
2001-159618 Jun 2001 JP
2001-305096 Oct 2001 JP
2001-330581 Nov 2001 JP
2002-502045 Jan 2002 JP
2002-514453 May 2002 JP
2003-180417 Jul 2003 JP
2004-000598 Jan 2004 JP
2004-500948 Jan 2004 JP
2004-117339 Apr 2004 JP
2004-522500 Jul 2004 JP
2004-528936 Sep 2004 JP
2005-503538 Feb 2005 JP
2005-087613 Apr 2005 JP
2006-512969 Apr 2005 JP
2005-525149 Aug 2005 JP
2005-237938 Sep 2005 JP
2005-525846 Sep 2005 JP
2005-527254 Sep 2005 JP
2006-512974 Apr 2006 JP
2006-516723 Jul 2006 JP
2006-521555 Sep 2006 JP
2006-527013 Nov 2006 JP
2007-521031 Aug 2007 JP
WO-9114212 Sep 1991 WO
WO-9413203 Jun 1994 WO
WO-9510223 Apr 1995 WO
WO-9510223 Apr 1995 WO
WO-9604857 Feb 1996 WO
WO-9614026 May 1996 WO
WO-9625088 Aug 1996 WO
WO-9715227 May 1997 WO
WO-9729847 Aug 1997 WO
WO-9730344 Aug 1997 WO
WO-9741421 Nov 1997 WO
WO-9831275 Jul 1998 WO
WO-9835225 Aug 1998 WO
WO-9912008 Mar 1999 WO
WO-9944508 Sep 1999 WO
WO-9958051 Nov 1999 WO
WO-0009184 Feb 2000 WO
WO-0013573 Mar 2000 WO
WO-0014269 Mar 2000 WO
WO-0014535 Mar 2000 WO
WO-0018449 Apr 2000 WO
WO-0018449 Apr 2000 WO
WO-0036400 Jun 2000 WO
WO-0042422 Jul 2000 WO
WO-0074763 Dec 2000 WO
WO-0074763 Dec 2000 WO
WO-0078208 Dec 2000 WO
WO-0116575 Mar 2001 WO
WO-0152727 Jul 2001 WO
WO-0164105 Sep 2001 WO
WO-0164105 Sep 2001 WO
WO-0172220 Oct 2001 WO
WO-0180728 Nov 2001 WO
WO-0185233 Nov 2001 WO
WO-0185233 Nov 2001 WO
WO-0191634 Dec 2001 WO
WO-0191634 Dec 2001 WO
WO-0200101 Jan 2002 WO
WO-0200101 Jan 2002 WO
WO-0249507 Jun 2002 WO
WO-0249509 Jun 2002 WO
WO-0249509 Jun 2002 WO
WO-02082052 Oct 2002 WO
WO-02082052 Oct 2002 WO
WO-02093144 Nov 2002 WO
WO-02100251 Dec 2002 WO
WO-02100251 Dec 2002 WO
WO-02101359 Dec 2002 WO
WO-02101359 Dec 2002 WO
WO-03030984 Apr 2003 WO
WO-03066128 Aug 2003 WO
WO-03066128 Aug 2003 WO
WO-03070099 Aug 2003 WO
WO-03071940 Sep 2003 WO
WO-03071940 Sep 2003 WO
WO-2004062499 Jul 2004 WO
WO-2004062500 Jul 2004 WO
WO-2004062500 Jul 2004 WO
WO-2004064636 Aug 2004 WO
WO-2005006939 Jan 2005 WO
WO-2005006939 Jan 2005 WO
WO-2005009238 Feb 2005 WO
WO-2005018709 Mar 2005 WO
WO-2005018709 Mar 2005 WO
WO-2005084546 Sep 2005 WO
WO-2005084546 Sep 2005 WO
WO-2005085995 Sep 2005 WO
WO-2007041063 Apr 2007 WO
WO-2007041063 Apr 2007 WO
WO-2007041244 Apr 2007 WO
WO-2007041244 Apr 2007 WO
WO-2007041287 Apr 2007 WO
WO-2007041287 Apr 2007 WO
WO-2007041355 Apr 2007 WO
WO-2007041355 Apr 2007 WO
WO-2011065981 Jun 2011 WO
Non-Patent Literature Citations (35)
Entry
Ada Consensus Development Panel. (Jan.-Feb. 1987). “Consensus Statement on Self-Monitoring of Blood Glucose,” Diabetes Care 10(1):95-99.
Ada (Jan. 1994). “Self-Monitoring of Blood Glucose,” Consensus Statement Diabetes Care 17(1):81-86.
Anonymous. (Sep. 30, 1993). “The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus.” The New England Journal of Medicine 329(14):977-986.
Anonymous. (Jun. 23, 1998). “Taking the “Ouch” Out of Needles: Arrays of “Microneedles” Offer New Techniques for Drug Delivery,” Science Daily, located at <http:www.sciencedaily.com/releases/1998/06/980623045850.htm>, last visited Jan. 14, 2014, 3 pages.
Beregszàszi, M. et al. (Jul. 1997). “Nocturnal Hypoglycemia in Children and Adolescents with Insulin-Dependent Diabetes Mellitus: Prevalence and Risk Factors,” J. Pediatrics 131(1 Pt. 1):27-33.
Chase, H.P. et al. (Feb. 2001). “Continuous Subcutaneous Glucose Monitoring in Children with Type 1 Diabetes,” Pediatrics 107(2):222-226.
Clarke, W.L. et al. (Sep.-Oct. 1987). “Evaluating Clinical Accuracy of Systems for Self-Monitoring of Blood Glucose,” Diabetes Care 10(5):622-628.
Collison, M.E. et al. (Sep. 1999). “Analytical Characterization of Electrochemical Biosensor Test Strips for Measurement of Glucose in Low-Volume Interstitial Fluid Samples,” Clinical Chemistry 45(9):1665-1673.
Cox, D.J. et al. (Jun. 1997). “Understanding Error Grid Analysis,” Diabetes Care 20(6):911-912.
D'Arrigo, T.D. (Mar. 2000). “GlucoWatch Monitor Poised for Approval,” Diabetes Forecast, 53(3):43-44.
Feldman, B. et al. (2000). “FreeStyleI M: A Small-Volume Electrochemical Glucose Sensor for Home Blood Glucose Testing, Diabetes Technology and Therapeutics,” 2(2):221-229.
International Search Report mailed Jan. 28, 2011, for PCT Application No. PCT/US2010/003063, filed on Nov. 30, 2010, 1 page.
Johnson, R.N. et al. (Jan. 1998). “Accuracy of Devices Used for Self-Monitoring of Blood Glucose,” Annals of Clinical Biochemistry 35(1):68-74.
Johnson, R.N. et al. (Jan. 1999). “Analytical Error of Home Glucose Monitors: A Comparison of 18 Systems,” Annals of Clinical Biochemistry 36(1):72-79.
Johnson, R.N. et al. (2001). “Error Detection and Measurement in Glucose Monitors,” Clinica Chimica Acta 307:61-67.
Kumetrix, Inc. (Dec. 1999). “Painless Blood Glucose Monitoring, Courtesy of the Mosquito,” Start-Up pp. 27-28.
Lee, S-C. (Jun. 1999). “Light Scattering by Closely Spaced Parallel Cylinders Embedded in a Finite Dielectric Slab,” Journal of the Optical Society of America A 16(6):1350-1361.
Mahler, R.J. et al. (1999). “Clinical Review 102, Type 2 Diabetes Melitus: Update on Diagnosis Pathophysiology, and Treatment,” The Journal of Clinical Endocrinology and Metabolism 84(4):1165-1171.
McGarraugh, G. et al. (2001). “Physiological Influences on Off-Finger Glucose Testing,” Diabetes Technology & Therapeutics 3(3):367-376.
McNichols, R.J. et al. (Jan. 2000). “Optical Glucose Sensing in Biological Fluids: An Overview,” Journal of Biomedical Optics, 5(1):5-16.
Medline Plus. (Jun. 17, 2008). , Medical Encyclopedia, Monitor Blood Glucose-Series: Part 1-4, 6 pages.
Neeley, W.E. et al. (1981). “An Instrument for Digital Matrix Photometry,” Clinical Chemistry 27(10):1665-1668.
Neeley, W.E. (1983). “Reflectance Digital Matrix Photometry,” Clinical Chemistry 29(6):1038-1041.
Neeley, W.E. (1983). “Multilayer Film Analysis for Glucose in 1- μL Samples of Plasma,” Clinical Chemistry 29(12):2103-2105.
Neeley, W.E. (1988). “A Reflectance Photometer with a Square Photodiode Array Detector for Use on Multilayer Dry-Film Slides,” Clinical Chemistry 34(11):2367-2370.
Otto, E. et al. (2000). “An Intelligent Diabetes Software Prototype: Predicting Blood Glucose Levels and Recommending Regimen Changes,” Diabetes Technology and Therapeutics 2(4):569-576.
Pfohl, M. et al. (2000). “Spot Glucose Measurement in Epidermal Interstitial Fluid—An Alternative to Capillary Blood Glucose Estimation,” Experimental and Clinical Endocrinology & Diabetes 108(1):1-4.
Princen, H.M. (May 1969). “Capillary Phenomena in Assemblies of Parallel Cylinders, I. Capillary Rise Between Two Cylinders,” Journal of Colloid and Interface Science 30(1):69-75.
Princen, H.M. (Jul. 1969). “Capillary Phenomena in Assemblies of Parallel Cylinders, II. Capillary Rise in Systems with More Than Two Cylinders,” Journal of Colloid and Interface Science 30(3):359-371.
Rebrin, K. et al. (Sep. 1999). “Subcutaneous Glucose Predicts Plasma Glucose Independent of Insulin: Implications for Continuous Monitoring,” American Journal of Physiology 277(3):E561-E571.
Smart, W.H. et al. (2000). “The Use of Silicon Microfabrication Technology in Painless Glucose Monitoring, ”Diabetes Technology & Therapeutics 2(4):549-559.
Svedman, C. et al. (Apr. 1999). “Skin Mini-Erosion Technique for Monitoring Metabolites in Interstitial Fluid: Its Feasibility Demonstrated by OGTT Results in Diabetic and Non-Diabetic Subjects,” Scand. J. Clin. Lab. Invest. 59(2):115-123.
Trinder, P. (1969). “Determination of Glucose in Blood Using Glucose Oxidase with an Alternate Oxygen Acceptor,” Annals of Clinical Biochemistry 6:24-28.
Written Opinion mailed Jan. 28, 2011, for PCT Application No. PCT/US2010/003063, filed on Nov. 30, 2010, 6 pages.
Yum, S. I. et al. (Nov. 1, 1999). “Capillary Blood Sampling for Self-Monitoring of Blood Glucose,” Diabetes Technology & Therapeutics, 1(1):29-37.
Related Publications (1)
Number Date Country
20110294152 A1 Dec 2011 US
Provisional Applications (2)
Number Date Country
61358791 Jun 2010 US
61265247 Nov 2009 US